Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
NCT ID: NCT06513273
Last Updated: 2025-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
397 participants
OBSERVATIONAL
2025-07-11
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96
NCT04589728
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
NCT04174612
Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia
NCT01452646
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00091234
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. AML diagnosis according to the ELN guidelines, excluding M3
3. Signed Informed consent, if applicable
4. Treatment initiation with novel drugs in monotherapy or combination, in accordance with the AIFA authorizations, from the AIFA registration up to 31.12.2027 with particular attention to:
* patients affected by FLT3-mutated AML treated with gilteritinib.
* patients affected by IDH-mutated AML treated with IDH inhibitors.
* patients affected by AML in maintenance therapy with oral azacytidine.
* patients affected by AML treated with glasdegib.
* patients affected by AML treated with gemtuzumab ozogamicin.
* other novel drugs or combination for the treatment of AML approved during the study period.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano Malattie EMatologiche dell'Adulto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Candoni
Role: PRINCIPAL_INVESTIGATOR
Haematology, University of Modena and Reggio Emilia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ematologia Ente Ecclesiastico Casa Sollievo Della Sofferenza
San Giovanni Rotondo, , Italy
UOC Ematologia AOU di SASSARI
Sassari, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Angelo Michele Carella
Role: primary
Claudio fOZZA
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AML2824
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.